News

November 15, 2019December 5, 2019

Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy May Benefit Myeloma Patients, Phase 1 Trial Shows

News

Adding the lymphoma therapy vorinostat to Revlimid (lenalidomide) maintenance therapy may deepen responses to stem cell transplants and prolong survival outcomes in multiple myeloma patients, long-term results of a ... Read more

November 13, 2019

CRISPR-edited T-cells Safely, Effectively Target Cancer Cells in Myeloma Patients, Early Phase 1 Data Suggests

News

A new approach using genetically modified T-cells — via CRISPR-Cas9 gene editing technology — safely and effectively targets cancer cells in patients with advanced multiple myeloma, preliminary data from ... Read more

November 11, 2019December 5, 2019

Nektar Launches First-in-Human Trial Testing NKTR-255 in Myeloma, Non-Hodgkin’s Lymphoma

News

Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial to assess the safety and efficacy of NKTR-255 in adults with relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma. “We are ... Read more

November 8, 2019

Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Teneobio‘s bispecific antibody TNB-383B as a possible treatment of multiple myeloma. Orphan drug designation provides Teneobio with benefits, including ... Read more

November 6, 2019December 5, 2019

Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows

News

U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio ... Read more

November 4, 2019December 5, 2019

Darzalex Combo Approved in Canada for Newly Diagnosed Myeloma Patients Ineligible for Transplant

News

Health Canada has approved Darzalex (daratumumab), in combination with standard Revlimid (lenalidomide) and dexamethasone, for people newly diagnosed with multiple myeloma who are not eligible for an autologous stem cell transplant. ... Read more

November 1, 2019

Next Up for ‘Moving Mountains for Multiple Myeloma’ — Patagonia

News

With the goal of encouraging the multiple myeloma community while raising money to advance treatments, Moving Mountains for Multiple Myeloma (MM4MM) is gearing up for its next expedition — Patagonia. The Nov. 9–19 ... Read more

October 30, 2019

CARsgen’s CT053 Receives RMAT Status from FDA for Multiple Myeloma Treatment

News

The U.S. Food and Drug Administration (FDA) has granted its Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational therapy CT053 for the treatment of relapsed or refractory multiple ... Read more

October 28, 2019

I-Mab Expands its Ongoing Myeloma Clinical Trials of MOR202 to China

News

I-Mab Biopharma is expanding to mainland China its ongoing clinical studies assessing MorphoSys‘ investigational antibody therapy MOR202 (TJ202) as treatment for people with multiple myeloma, the company announced. The ... Read more

October 25, 2019

CHMP Recommends Darzalex Triple Combo for Some Newly Diagnosed Multiple Myeloma Patients in EU

News

The European Medicines Agency (EMA) has recommended that Darzalex (daratumumab) be approved in Europe, in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for multiple myeloma patients who are ineligible for autologous ... Read more

Pin It on Pinterest